Conversations with Dr Julie Suman, on Nasal Drug Delivery: Current trends, technical challenges and opportunities for therapeutic innovation
Aptar Pharma present data on the challenges and opportunities for Nasal drug delivery.
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant
Discover Nanopharm’s breakthrough in dry-powder HPV vaccines. Learn how GLA enhances aerodynamic performance for effective inhalation delivery of the antigen.
Nanopharm’s Nasal Spray for SARS-CoV-2 Antibody Treatment
Discover Nanopharm’s innovative nasal spray for SARS-CoV-2. Learn how this prophylactic treatment effectively delivers antibodies for maximum protection.
Fundamental properties of propellant aerosols can guide transition to low global warming potential pMDIs: size, velocity and surface charge
Discover Nanopharm’s groundbreaking research on Low GWP propellants in pMDIs. Learn how they revolutionize drug delivery and the role of valve and actuators.
Nanopharm: Valve Types & Container Systems in pMDIs with Salmeterol
Explore Nanopharm’s study on the impact of valve types and container closure systems in pMDIs. Focus on formulations with Salmeterol Xinafoate and how they perform under stressed conditions.
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
Understand how particle size impacts inhalation drug delivery and the role of dry powder inhalers (DPIs) in treating respiratory diseases.
The Role of In Silico Regional Deposition Modelling and Pharmacokinetic Profiling in the Development of a Generic Tiotropium Dry Powder Inhaler
Nanopharm explores In Silico methods in the development of a Generic Tiotropium Dry Powder Inhaler (DPI). Learn how drug absorption is impacted.
The influence of blend composition on the aerodynamic performance of a novel high resistance multi-dose device
Explore the study by Irene Rossi on blend composition’s influence on Aptar Prohaler®. Insights into FPM, MMAD, and aerodynamic performance in COPD treatment
In Vitro and In Silico Comparison of Indacaterol and Glycopyrrolate Pulmonary Deposition between a Single-Unit Dose and a Multi-Unit Dry Powder Inhaler
In-depth study by Nanopharm on In Vitro and In Silico comparison of Indacaterol and Glycopyrrolate in single-unit and multi-unit DPIs for COPD treatment.
